Tempest Therapeutics (TPST) EBITDA (2012 - 2026)

Tempest Therapeutics has disclosed EBITDA across 15 years of filings, most recently posting -$5.2 million for Q2 2026.

• In Q2 2026, EBITDA rose 34.09% year-over-year to -$5.2 million; the TTM figure through Jun 2026 stood at -$20.9 million (up 51.83% YoY), while the FY2025 annual figure was -$26.6 million, up 36.77% from the prior year.
• EBITDA came in at -$5.2 million for Q2 2026 at Tempest Therapeutics, down from -$4.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.6 million in Q3 2025 to a low of -$13.9 million in Q4 2024.
• Average EBITDA over 5 years is -$8.1 million, with a median of -$8.0 million recorded in 2024.
• Year-over-year, EBITDA plunged 85.23% in 2024 and jumped 70.71% in 2025.
• Over 5 years, EBITDA stood at -$8.9 million in 2022, then climbed by 15.89% to -$7.5 million in 2023, then sank by 85.23% to -$13.9 million in 2024, then surged by 70.71% to -$4.1 million in 2025, then dropped by 28.77% to -$5.2 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$5.2 million in Q2 2026, -$4.1 million in Q4 2025, and -$3.6 million in Q3 2025.